このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

COVID-19 患者における同種臍帯間葉系幹細胞の安全性と有効性を評価する (UMSC01)

2026年9月21日 更新者:Ever Supreme Bio Technology Co., Ltd.

COVID-19 重篤かつ重篤な状態の患者における同種臍帯間葉系幹細胞の安全性と有効性を評価するためのシームレスな第 I/IIa 相臨床試験

This study is to explore the safety and efficacy of using UCMSC01 in patients with COVID-19 infection via IV stem cell administration. The novelty of the current UMSC01 treatment is the single IV infusion of UMSC01 to the worldwide emergency outbreaks of COVID-19. We hypothesize that sufficient UMSC01 retention in lung may modulate the systemic inflammatory responses.

調査の概要

詳細な説明

The lead Phase I safety phase will further confirm the safety profile of UMSC01 in 5 COVID-19 patients each at two dose regimens and placebo.

To start the Phase IIa study, data analysis will be performed as soon as the 21-day treatment period has been completed in the three groups. With considerations of the pandemic status and clinical practice, only one of the two active treatment groups will be selected to complete the Phase IIa study, which will recruit 60 patients.

研究の種類

介入

入学 (推定)

75

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Non-US
      • Taichung、Non-US、台湾、404
        • China Medical University Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

20年~80年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Male or female aged 20 to 80 years old.

  2. Hospitalized severe and critical COVID-19 patients with laboratory confirmation by reverse-transcription polymerase chain reaction (RT-PCR) from nasopharyngeal/ oropharyngeal samples collected using standardized method.

  3. Pneumonia or interstitial lung damage that is confirmed by chest radiographs or computed tomography.

  4. Severe COVID-19 infection which meets any one of the following: 1) dyspnea (PR ≥ 30 times/min), 2) finger oxygen saturation ≤ 93% in the room air and resting state, 3) arterial oxygen partial pressure (PaO2)/oxygen absorption concentration (FiO2) ≤ 300 mmHg, 4) pulmonary imaging which shows that the focus progress > 50% within 24-48 hours, or

  5. Critically severe COVID-19 infection which meets any of the following: 1) respiratory failure treated by mechanical ventilation, 2) shock, 3) combined with other organ failure, 4) patients expected to need ICU monitoring and treatment.

  6. High sensitivity C-reactive protein (hs-CRP) serum level > 4.0 mg/dL.

  7. All female patients with child-bearing potential (between puberty and 2 years after menopause) should use appropriate contraception method(s) shown below, for at least 4 weeks after UMSC01 treatment and agree to maintain such contraceptive method(s) for another 4 weeks after UMSC01 treatment.

    1. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
    2. Female sterilization (bilateral oophorectomy with or without hysterectomy) or tubal ligation at least 6 weeks before taking study treatment. In case of oophorectomy alone, the reproductive status of the woman should be confirmed by the hormone level assessment.
    3. Male sterilization (at least 6 months prior to screening). For female subjects in the study, the vasectomized male partner should be the sole partner for that subject.
    4. Combination of any two of the following listed methods: (d.1 + d.2 or d.1 + d.3, or d.2 + d.3):

    d.1 Use of oral, injected, or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), such as hormone vaginal ring or transdermal hormone contraception.

    d.2 Placement of an intrauterine device (IUD) or intrauterine system (IUS). d.3 Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository.

Exclusion Criteria:

  1. Pregnancy, lactation, and those who are not pregnant but did not, or unwilling to, take effective contraceptives measures 4 weeks before and after the treatment.
  2. Patients with malignant tumors or other serious systemic diseases.
  3. Patients with hemoglobin < 10 g, alanine aminotransferase (ALT) ≥ 5 × ULN, aspartate aminotransferase (AST) ≥ 5 × ULN, alkaline phosphatase (ALP) ≥ 5 × ULN, total bilirubin (TBILI) ≥ 2 × ULN, serum creatinine > 2.5 mg/dl, platelet counts < 100,000/μL, WBC < 3,000 cells/μL, or neutrophil counts < 1,000/μL at screening.
  4. Presence of barotrauma or hemodynamic instability defined as hypotension with diastolic blood pressure < 90 mmHg or mean arterial pressure (MAP) < 70 mmHg despite fluid expansion, and vasoactive support or pneumothorax at screening.
  5. Uncontrolled hypertension with systolic blood pressure > 170 mmHg and diastolic blood pressure > 100 mmHg which, in the investigator's judgment, would not make participation appropriate.
  6. Recent history of (within 2 years) ischemic heart disease or cerebrovascular attack, such as myocardial infarction, unstable angina, or stroke.
  7. Recent history (within 2 years) of hypercoagulable disorder, antiphospholipid syndrome, pulmonary embolism, or deep venous thrombosis.
  8. Condition other than COVID-19 that is projected to limit lifespan to ≤ 1 year.
  9. History of drug or alcohol abuse within the past 24 months.
  10. Unwilling to commit to follow-up visits.
  11. Patients who are participating in other clinical trials with an investigational product.
  12. Co-infection of HIV, tuberculosis, influenza virus, adenovirus, and other respiratory infection virus.
  13. Patients with other conditions that are not suitable to participate in this clinical study as determined by the investigator.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:UMSC01

UMSC01 cells mixed with normal saline will be administered to patients after COVID-19 infection.

UMSC01 cells will be IV infusion with 12 months of follow up after treatment.

プラセボコンパレーター:Placebo

Normal saline will be administered to patients after COVID-19 infection.

Normal saline will be IV infusion with 12 months of follow up after treatment.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Two Co-Primary Efficacy Endpoints
時間枠:21 days of the treatment period

Proportion of patients alive with sustained improvement within the 21 days of the treatment period (Proportion Analysis), which indicates the capability of UMSC01 to save more lives

21 days of the treatment period
Two Co-Primary Efficacy Endpoints
時間枠:21 days of the treatment period

Time (days) to reach sustained improvement within the 21 days of the treatment period (Time-to-Event Analysis), which indicates the capability of UMSC01 to enable patients to less suffer from the disease condition.

21 days of the treatment period

二次結果の測定

結果測定
メジャーの説明
時間枠
Secondary Efficacy Endpoints
時間枠:21 days of the treatment period

Proportion of enrolled patients alive on Day 21

21 days of the treatment period
Secondary Efficacy Endpoints
時間枠:21 days of the treatment period

Proportion of enrolled patients alive and free of respiratory failure on Day 21

21 days of the treatment period
Secondary Efficacy Endpoints
時間枠:21 days of the treatment period

Improvement of COVID 19 pneumonia confirmed by chest radiographs or computed tomography on Day 21 or on the day of discharge compared with baseline

21 days of the treatment period
Secondary Efficacy Endpoints
時間枠:21 days of the treatment period

Improvement of clinical symptoms including duration of fever in degrees C and respiratory failure on Day 21 or on the day of discharge compared with baseline

21 days of the treatment period
Secondary Efficacy Endpoints
時間枠:21 days of the treatment period

Duration of ventilator usage or oxygen therapy on Day 21 or on the day of discharge compared with baseline

21 days of the treatment period
Secondary Efficacy Endpoints
時間枠:21 days of the treatment period

Levels of tumor necrosis factor-alpha (TNF-α) in pg/ml, interleukin-6 (IL-6) in pg/ml and interleukin-10 (IL-10) in pg/ml, and C-reactive protein (hsCRP) in mg/dl on Day 21 or on the day of discharge compared to baseline

21 days of the treatment period
Secondary Efficacy Endpoints
時間枠:21 days of the treatment period

Troponin I level as assessed via serum blood samples on Day 21 or on the day of discharge compared with baseline

21 days of the treatment period
Secondary Efficacy Endpoints
時間枠:21 days of the treatment period

ICU admission rate on Day 21 or on the day of discharge with historical data

21 days of the treatment period
Secondary Efficacy Endpoints
時間枠:14 days of the treatment period

Percentage of subjects recorded in each severity rating based on Clinical classification of the COVID-19 (NCOSS scores from 1 to 8;higher scores mean a worse outcome) on Day 14 compared with historical data

14 days of the treatment period
Secondary Efficacy Endpoints
時間枠:21 days of the treatment period

Percentage of subjects recorded in each severity rating based on Clinical classification of the COVID-19 (NCOSS scores from 1 to 8;higher scores mean a worse outcome) on Day 21 compared with historical data

21 days of the treatment period
Secondary Efficacy Endpoints
時間枠:through study completion, an average of 1 year

Average time (days) for which the patients are alive and free of respiratory failure during the treatment period

through study completion, an average of 1 year
Secondary Efficacy Endpoints
時間枠:21 days of the treatment period

Proportion of patients who need ICU care on Day 21 based on the clinical indicative of admission to ICU

21 days of the treatment period
Secondary Efficacy Endpoints
時間枠:21 days of the treatment period

Proportion of patients who has been discharged form hospital on Day 21

21 days of the treatment period
Secondary Safety Endpoints
時間枠:21 days of the treatment period

Number of Participants with infusion-related and allergic reactions during the treatment period

21 days of the treatment period
Secondary Safety Endpoints
時間枠:through study completion, an average of 1 year

Secondary infection, treatment emergent adverse event (TEAE), serious adverse event (SAE), and suspected and unexpected serious adverse reaction (SUSAR) incidences over the study period. The toxicities will be assessed by CTCAE V5.0 during the whole study period (380 days)

through study completion, an average of 1 year

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • スタディディレクター:Woei C Shyu、Ever Supreme Bio Technology Co., Ltd.
  • 主任研究者:Long Bin Jeng、China Medical University Hospital

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2020年8月5日

一次修了 (推定)

2027年12月31日

研究の完了 (推定)

2027年12月31日

試験登録日

最初に提出

2022年8月10日

QC基準を満たした最初の提出物

2022年8月11日

最初の投稿 (実際)

2022年8月15日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月23日

QC基準を満たした最後の更新が送信されました

2026年9月21日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する